Luis Castelo-Branco: We need serious reflections on futile/marginal expected benefit when designing a trial

Bishal Gyawali shared a post by Luis Castelo-Branco, Medical Oncologist and doctor of public health at IOSI, on X:

“Well, I am not surprised that its olaparib. One more example to add to this list.”

Quoting Luis Castelo-Branco‘s post:

“We need serious reflections on futile/marginal expected benefit when designing a trial. We have plenty of examples (as this one) where the benefit was unlikely to be relevant. Should the rational for a trial be more rigorously and ethically assessed?”

Source: Bishal Gyawali/X and Luis Castelo-Branco/X

Bishal Gyawali, MD, PhD, is a medical oncologist from Nepal. Currently an Associate Professor at Queen’s University, Kingston, Canada, and affiliated with Brigham and Women’s Hospital, Boston, USA, he is involved in global oncology initiatives. Dr. Gyawali serves on several committees, including the WHO Essential Medicines List Cancer Medicines Working Group and ASCO’s Health Equity and Outcomes Committee, contributing significantly to cancer policy and evidence-based oncology.